Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer
Condition: Breast Neoplasms Interventions: Drug: Olaparib; Drug: Durvalumab Sponsors: Seoul National University Hospital; AstraZeneca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | Hospitals | Neoadjuvant Therapy